Clinical Trial Update: Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma [Phase 2]

View source ↗

Summary

Update on a Phase 2 pediatric trial evaluating atezolizumab in 2-17 year-olds with clear cell sarcoma or advanced central chondrosarcoma, including central chon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Chondrosarcoma
• Clear Cell Sarcoma of Soft Tissue
• Dedifferentiated Chondrosarcoma
• Unresectable Primary Central Chondrosarcoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-23